Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review

Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off‐label use of a 48 weeks course of PegInterferon alpha (PegIFNα), that was characterized by suboptimal efficacy and burdened by significant side effects t...

Full description

Saved in:
Bibliographic Details
Published inJournal of viral hepatitis Vol. 30; no. S1; pp. 26 - 32
Main Authors Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.04.2023
Subjects
Adult
Antiviral Agents - adverse effects
Antiviral drugs
bulevirtide
chronic delta hepatitis
Cirrhosis
Clinical trials
combined response
entry inhibitor
HDV
HDV‐RNA
Hepatitis
Hepatitis Delta Virus
Hepatitis, Chronic - drug therapy
Humans
Liver diseases
Patients
Treatment Outcome
virological response
entry inhibitor
bulevirtide
virological response
chronic delta hepatitis
HDV-RNA
combined response
HDV
cirrhosis
Online AccessGet full text

Cover

More Information
Summary:Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off‐label use of a 48 weeks course of PegInterferon alpha (PegIFNα), that was characterized by suboptimal efficacy and burdened by significant side effects that limited treatment applicability in patients with advanced liver disease. In July 2020, European Medicines Agency (EMA) conditionally approved the entry inhibitor Bulevirtde (BLV) at the dose of 2 mg/day for the treatment of adult patients with compensated CHD. Efficacy and safety of BLV in CHD have been evaluated in clinical trials either as monotherapy or in combination with PegIFNα. These results were confirmed by real‐life studies, which also evaluated long‐term BLV monotherapy in patients with advanced compensated cirrhosis. Notwithstanding these promising results there are still several issues to be addressed, such as the optimal duration of the treatment, the rates of off‐therapy responses, as well as the long‐term clinical benefits. This review summarizes updated and current literature data about clinical trials and real‐life studies with BLV monotherapy and/or in combination with PegIFNα.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1352-0504
1365-2893
1365-2893
DOI:10.1111/jvh.13811